Abstract 1444P
Background
In the United States, uniquely American risk factors have led to a rise in the incidence of esophageal adenocarcinoma. In contrast, Asians have generally shown a predominance of esophageal squamous cell carcinoma (SCC), and this has held among Asian-Americans. However, limited investigation of esophageal cancer within Asian-Americans has been conducted in recent years.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Incidence Database was queried for patients from 2004-2020 classified as Asian/Pacific Islander and diagnosed with esophageal adenocarcinoma or squamous cell carcinoma. Descriptive statistics and multivariate models were utilized to compare incidence, cancer characteristics, treatment details, and survival in patients with esophageal adenocarcinoma and SCC.
Results
During this time, 2103 (73.71%) Asian-Americans presented with esophageal SCC compared to 750 (26.29%) with adenocarcinoma. Patients with SCC were diagnosed at a significantly older age (68.09 vs 66.10, p=<0.0001) and had a larger distribution of females (28.72% vs 15.20%, p<0.0001) than those with adenocarcinoma. The distribution of tumor stage was significantly different across these two groups (p<0.0001), with 292 (38.93%) adenocarcinoma patients diagnosed at stage IV compared to 546 (25.96%) patients with SCC. Cox regression analysis revealed that SCC was independently associated with worse survival (Hazard Ratio 1.115 (1.08-1.233)) compared to esophageal adenocarcinoma. Table: 1444P
Histological subtype | p-value | ||
Squamous cell carcinoma (N = 2103), N (%) | Adenocarcinoma (N = 750), N (%) | ||
Age, mean (years) | 68.09 | 66.10 | <0.0001 |
Sex | <0.0001 | ||
Female | 604 (28.72) | 114 (15.20) | |
Male | 1499 (71.28) | 636 (84.80) | |
Derived stage | <0.0001 | ||
I | 196 (9.32) | 72 (9.60) | |
II | 379 (18.02) | 97 (12.93) | |
III | 547 (26.01) | 166 (22.13) | |
IV | 546 (25.96) | 292 (38.93) | |
Unknown | 435 (20.68) | 123 (16.40) | |
Location of tumor | <0.0001 | ||
Upper third | 276 (13.12) | 11 (1.47) | |
Middle third | 692 (32.91) | 43 (5.73) | |
Lower third | 547 (26.01) | 566 (75.47) | |
Unclear/NOS | 588 (27.96) | 130 (17.33) | |
Cause of death | <0.0001 | ||
Alive | 452 (21.49) | 177 (23.6) | |
Esophageal cancer | 1300 (61.82) | 411 (54.8) | |
Other cause of death | 351 (16.69) | 162 (21.6) |
Conclusions
SCC remains the predominant histological subtype of esophageal cancer within Asian-Americans. Several factors may contribute to this, including BMI, immigration history, and retained cultural practices. However, adenocarcinoma should not be missed in this cohort. The later stage diagnosis of adenocarcinoma suggests that methods to improve early detection are necessary, and poorer survival of the SCC cohort indicates an opportunity to improve treatment paradigms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1919P - Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Presenter: Luigi Cerbone
Session: Poster session 18
Resources:
Abstract
1918P - Real-world efficacy and toxicity of combination immunotherapy in mesothelioma: North East of England experience
Presenter: Manal Elgendy
Session: Poster session 18
Resources:
Abstract
1917P - Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma
Presenter: Vilde Haakensen
Session: Poster session 18
Resources:
Abstract
1916P - Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study
Presenter: LUANA CALABRO
Session: Poster session 18
Resources:
Abstract
1915P - Phase I trial of adjuvant pembrolizumab after radiation therapy for lung-intact malignant pleural mesothelioma
Presenter: Matthew Ning
Session: Poster session 18
Resources:
Abstract
1914P - Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Presenter: Omar Abdel-Rahman
Session: Poster session 18
Resources:
Abstract
1913P - Five year results of transbronchial microwave ablation of lung malignancies with electromagnetic navigation guidance
Presenter: Joyce Chan
Session: Poster session 18
Resources:
Abstract
1912P - AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
Presenter: Samaantha Bove
Session: Poster session 18
Resources:
Abstract
1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France
Presenter: Laurent Greillier
Session: Poster session 18
Resources:
Abstract